Orexigen Therapeutics (OREX) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil steadies on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
August 4, 2016 4:01 PM EDTSAN DIEGO, Aug. 4, 2016 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2016.
"Earlier this week we completed our acquisition of U.S. rights to Contrave®, transforming Orexigen into a fully integrated commercial pharmaceutical company focused on our mission to improve the health and lives of patients struggling to lose weight," said Mike Narachi, CEO of Orexigen. "With the completion of this acquisition and the development of our independent commercialization capabilities over the past several months,... More
